Abstract
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a hypersensitivity reaction characterized by maculopapular rash, exfoliative dermatitis, lymphadenopathy, fever, eosinophilia, and involvement of internal organs. Evidence for reactivation of herpes family viruses has been observed in some DRESS patients, and activated CD8+ T lymphocytes are largely directed against Epstein-Barr virus. Here, we report two cases complicated with this infection. Both patients received antibiotics and non-steroidal anti-inflammatory drugs. These patients manifested clinically with high fever, facial edema, diffuse pruritic erythroderma and maculopapules over the entire body, purpuric rashes in both lower limbs and lymphadenopathy of cervical and inguinal nodes. Laboratory tests revealed abnormal liver function, blood eosinophils, and ferritin levels. The patients recovered completely; however, the female patient developed hemophagocytic syndrome on the 15th day of illness. She developed new itchy rash, and laboratory tests rapidly worsened with fibrinogen levels dramatically reduced to 0.61 g/L. Bone marrow aspiration revealed an increased number of macrophages with hemophagocytosis and a reversed CD4/CD8 ratio of 0.45. These cases suggest that human herpes virus and coagulation function evaluations are necessary in DRESS patients.
Drug reaction with eosinophilia and systemic symptoms (DRESS) affects multiple organs and is occasionally associated with activation of viruses, such as human herpes virus (HHV)-6, HHV-7, Epstein-Barr virus (EBV), and cytomegalovirus, in the setting of drug hypersensitivities1. In some cases, these active viruses can cause further hematological disorders. Here, we report two cases of such complications.
Both cases were in middle age and suffered from high fever for 9~21 days followed by onset of generalized pruritic eruptions. Before the skin rashes appeared, both patients received antibiotics and non-steroidal anti-inflammatory drugs (Table 1). Dermatological examinations are described in Fig. 1A, B, D, E. Lymphadenopathies were revealed in cervical and inguinal areas, and splenomegaly was also present in both patients. Skin pathology (Fig. 1C, F) and laboratory findings (Table 1) are provided. Due to positive findings of EBV-immunoglobulin M or deoxyribonucleic acid (DNA) copies of EBV, both patients were diagnosed as DRESS complicated with EBV infection. After treatment with methylprednisolone (40 mg/d), ganciclovir (250 mg, every 12 hours), and intravenous immunoglobins (20 g/d) for case 1 or plasma (200 ml/d) for case 2, the second patient recovered with darkening and diminishing of the eruption and a reduction of aminotransferases. However, on the fifteenth day of illness, case 1 developed new itchy rashes over the body and worsened purpura on extremities. Complete blood counts revealed a leukocyte count of 6.26×109/L and a platelet count of 46×109/L. Blood chemistry revealed progressively impaired liver and coagulation function (alanine aminotransferase 1,141 IU/L, aspartate aminotransferase 3,046 IU/L, lactate dehydrogenase 2,807 IU/L, prothrombin time 21.8 seconds (normal range: 9.0~11.5 seconds), activated partial thromboplastin time 49.2 seconds (normal range: 26.9~37.6 seconds), fibrinogen 0.61 g/L (normal range: 2~4 g/L). A bone marrow aspiration revealed an increased number of macrophages with hemophagocytosis and a reversed CD4/CD8 ratio (0.45). Hemophagocytic syndrome was timely diagnosed based on the above characteristics for this case. Methylprednisolone was increased to 60 mg/d, and plasma infusion was continued daily. The patient's organ dysfunctions recovered gradually, and the skin eruptions were eventually reduced the following week.
DRESS is fatal in approximately 10% of cases2. The most culprit drugs are allopurinol, carbamazepine, and sulfasalazine, and the condition is potentially worsened by β-lactam antibiotics3. Concomitantly, DRESS is possibly associated with proliferation of activated CD8+ T lymphocytes directed against viral antigens derived mostly from herpes viruses such as EBV4. Astonishingly, in a French report, 16 out of 38 (42%) patients experienced EBV reactivation5. By contrast, a recent study including 34 Japanese DRESS patients demonstrated that less than 10% of patients presented with increased EBV DNA levels. In addition, EBV DNA loads were significantly reduced in the steroid-treated group compared with the non-treated group, whereas cytomegalovirus and HHV-6 DNA loads were increased after steroid therapy6. Interestingly, our second case developed extensive activations of EBV, cytomegalovirus and herpes simplex virus, which is rarely reported in the literature.
Hemophagocytic syndrome is a disorder manifesting overlapping symptoms as DRESS and infectious mononucleosis, including fever, lymphadenopathy, hepatosplenomegaly, and macular rashes78. Infections (especially EBV), malignancies, or autoimmune diseases can induce this severe condition. DRESS and hemophagocytic syndrome was marked by abnormal T-cell activation; however, few DRESS cases developed hemophagocytic syndrome alone9. After seeking potential causes as noted above, we thus believe hemophagocytic syndrome in this case is likely due to the activation of EBV10. Particularly, this patient had a history of rheumatoid arthritis and a flare of this condition immediately before the drug hypersensitivity aroused by sulfasalazine intake, which is very similar to the case reported by Komatsuda et al.10 Although hemophagocytic syndrome contributed to the worsening background of several disorders, whether the condition was accentuated by this specific drug besides viral activation is not fully understood. Given that this complication developed quickly, blood count, coagulation function, and ferritin levels are useful for early diagnosis.
Our cases emphasized the necessities of HHV and coagulation evaluations in all DRESS patients. Early intervention of such complications may lead to a promising prognosis in these patients.
References
1. Nanishi E, Hoshina T, Ohga S, Nishio H, Hara T. Drug reaction with eosinophilia and systemic symptoms during primary Epstein-Barr virus infection. J Microbiol Immunol Infect. 2015; 48:109–112. PMID: 25074626.
2. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007; 156:609–611. PMID: 17300272.
3. Girelli F, Bernardi S, Gardelli L, Bassi B, Parente G, Dubini A, et al. A new case of DRESS syndrome induced by sulfasalazine and triggered by amoxicillin. Case Rep Rheumatol. 2013; 2013:409152. PMID: 23936716.
4. Drago F, Cogorno L, Broccolo F, Ciccarese G, Parodi A. A fatal case of DRESS induced by strontium ranelate associated with HHV-7 reactivation. Osteoporos Int. 2016; 27:1261–1264. PMID: 26519419.
5. Picard D, Janela B, Descamps V, D'Incan M, Courville P, Jacquot S, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010; 2:46ra62.
6. Ishida T, Kano Y, Mizukawa Y, Shiohara T. The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy. 2014; 69:798–805. PMID: 24749495.
7. Nishio D, Izu K, Kabashima K, Tokura Y. T cell populations propagating in the peripheral blood of patients with drug eruptions. J Dermatol Sci. 2007; 48:25–33. PMID: 17601705.
8. Filipovich AH. The expanding spectrum of hemophagocytic lymphohistiocytosis. Curr Opin Allergy Clin Immunol. 2011; 11:512–516. PMID: 21971331.
9. Picard M, Fernandez MI, Des Roches A, Bégin P, Paradis J, Paradis L, et al. Ceftazidime-induced drug reaction with eosinophilia and systemic symptoms (DRESS) complicated by hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol Pract. 2013; 1:409–412. PMID: 24565550.
10. Komatsuda A, Okamoto Y, Hatakeyama T, Wakui H, Sawada K. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. Clin Rheumatol. 2008; 27:395–397. PMID: 17952482.